You are here
AstraZeneca's immunotherapy drug wins key lung cancer approval
ASTRAZENECA'S immunotherapy drug Imfinzi has won crucial approval from US regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.
The US Food and Drug Administration said late on Friday that it
- CALL +65 6388 3838
- EMAIL firstname.lastname@example.org